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ABSTRACT 1 
Background.   Trajectory patterns of positive, disorganized and negative dimension symptoms 2 
during antipsychotic treatment in drug-naïve patients with first-episode psychosis have yet to be 3 
examined by using naturalistic data.  4 
Method. This pragmatic clinical trial randomized 161 drug- naïve patients with a first episode of 5 
psychosis to olanzapine, risperidone or haloperidol. Patients were assessed with the SANS and 6 
SAPS at baseline and at the end of weeks 1, 2, 3, 4 and 6 of antipsychotic treatment. Censored 7 
normal models of response trajectories were developed with three dimensions of the SAPS-8 
SANS scores (positive, disorganized and negative) in order to identify the different response 9 
trajectories. Diagnosis, cannabis use, duration of untreated psychosis (DUP), smoking and 10 
antipsychotic class were examined as possible predictive variables.  11 
Results. Patients were classified in five groups according to the positive dimension, three groups 12 
according to the disorganized dimension and five groups according to the negative dimension. 13 
Longer DUPs and cannabis use were associated with  higher scores and poorer responses in the 14 
positive dimension. Cannabis use was associated with higher scores and poorer responses in the 15 
disorganized dimension. Only schizophrenia diagnosis was associated with higher scores and 16 
poorer responses in the negative dimension.  17 
Conclusions. Our results illustrate the heterogeneity of short-term response to antipsychotics in 18 
patients with a first episode of psychosis and highlight markedly different patterns of response in 19 
the positive, disorganized and negative dimensions. DUP, cannabis use and diagnosis appeared 20 
to have a prognostic value in predicting treatment response with different implications for each 21 
dimension.  22 
  23 
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 2 
Introduction 3 
 Patients with schizophrenia are expected to exhibit reduced symptoms after an adequate 4 
antipsychotic treatment of 3 to 6 weeks. However, even during the first episode of psychosis, 5 
only 55 to 60% of patients will show a significant reduction in the severity of psychotic 6 
symptoms during the acute phase of the illness (Lieberman et al., 2003; Crespo-Facorro et al., 7 
2006). Current research in antipsychotic treatment response usually focuses on aggregate data 8 
that compare entire groups of patients, usually ignoring interindividual heterogeneity in response 9 
to treatment. An examination of heterogeneity may have a prognostic and clinical utility, since it 10 
may help to identify groups of responders and non-responders, the key periods of response in 11 
antipsychotic treatment and differences in the response profile for different antipsychotic 12 
treatments (Levine et al., 2012). Recent research has challenged the delayed response hypothesis 13 
in antipsychotic treatment, showing that a response may occur from the first week of 14 
antipsychotic treatment and that early responses predict subsequent responses (Agid et al., 2003; 15 
Leucht et al., 2005). The estimates of rapid response have been observed to range from one week 16 
(Correll et al., 2003) to two months (Emsley et al., 2006), and suggest a great variation in the 17 
magnitude and time of response.  18 
 Advances in statistical modeling allow examining the existence of different trajectories of 19 
symptom severity over time without a priori definitions such as a cut-off in the treatment 20 
response (Muthén et al., 2002; Muthén & Muthén , 2007). Accordingly, several studies have 21 
focused on the heterogeneity of response to antipsychotics, analyzing the pattern of these 22 
trajectories over time. Levine and Rabinowitz (2010) identified five response trajectories 23 
4 
 
 
 
following a latent class analysis approach in a sample of early-onset psychosis patients. They 1 
found four parallel trajectories with a modest response and distinguished a trajectory with a 2 
dramatic response during the first 4 weeks of treatment. Ensuing studies have replicated these 3 
results, with four (Marques et al., 2011; Case et al, 2011) or five (Levine et al., 2010; Stauffer et 4 
al., 2011) trajectories as a solution and groups with dramatic, poor or intermediate responses. 5 
Levine et al., (2012) reported finding three response trajectories in a post hoc study of the 6 
CATIE trial. However, these authors analyzed trajectories of treatment response assessed by 7 
PANSS percent reduction rather than symptom severity (PANSS scores), which renders a 8 
comparison of their results with prior trajectory analyses difficult. Interestingly, only one study 9 
focusing on a naturalistic intervention in previously treated patients has reported a similar pattern 10 
of five trajectories of response based on total PANSS scores (Schennach et al., 2012). Several 11 
predictors have been associated with belonging to particular trajectories including gender, age at 12 
illness onset, diagnosis, premorbid adjustment, cognitive performance, length of illness, 13 
depressive symptoms, social functioning, and early response to treatment, although there are 14 
contradictory results. The methodology of trajectory analysis has also been used to identify 15 
different courses of schizophrenia in a population –using patient cohorts and the number of 16 
hospitalized days as a proxy of deterioration course (Levine et al., 2011). 17 
 A number of methodological issues need to be addressed in the research of treatment 18 
response trajectories in schizophrenia, since replication and validation of its results may be 19 
difficult. More importantly, most studies have focused on trajectories of responses based on the 20 
total score of general psychopathological scales, such as the positive and negative syndrome 21 
scale (PANSS; Case et al., 2011;  Levine & Rabinowitz, 2010; Levine et al., 2010;2012; Stauffer 22 
et al., 2011) or the Brief Psychiatric Rating Scale (BPRS) (Levine & Leucht, 2010), but  only 23 
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three research groups have examined trajectories of positive and negative dimensions. Marques 1 
et al. (2011) were not able to find an appropriate model for the BPRS negative dimension, 2 
whereas Levine and Rabinowitz (2010) observed five response trajectories in the total PANSS 3 
and its positive and negative subscales but with less improvement in the negative subscale.  Case 4 
et al. (2011) found four trajectories for the PANSS negative subscale that were similar to the 5 
trajectories of PANSS total scale, and three trajectories for the PANSS positive subscale that did 6 
not include an “unsustained response” trajectory. Discriminating response on the basis of 7 
specific symptom dimensions may be a productive research approach to the study of response 8 
trajectories, given that there may be different pathological basis (Harvey et al., 2006) and courses 9 
(Levine & Leucht, 2012) for the positive and negative dimensions which contribute to patients’ 10 
heterogeneity. Moreover, some patient subsamples have demonstrated high drop-out rates that 11 
are associated with different trajectories (Levine & Leucht, 2010; Levine et al., 2012). These 12 
drop-out differences may bias the results of studies searching for trajectory predictors and reduce 13 
their generalizability. Finally, only a few studies of response trajectories have been performed 14 
using first-episode or early-psychosis patients (Levine & Rabinowitz 2010, Levine et al., 2010). 15 
The inclusion of chronic and previously-treated patients may increase response heterogeneity 16 
and also limit the probability of response. Studies based on representative first-episode samples 17 
like the one used in the current study may help to avoid or reduce these biases.  18 
 The objectives of the current research were: 1) to identify the number of distinct 19 
trajectories that best define antipsychotic response in a representative sample of drug-naïve first-20 
episode psychosis patients; 2) to examine whether distinct response trajectory patterns may be 21 
identified using different symptom dimensions of schizophrenia; and 3) to search for factors that 22 
predict response trajectories. This study is the first to explore the trajectories of the 3 widely 23 
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accepted schizophrenia dimensions (psychotic-reality distortion, negative and disorganized) by 1 
using a sophisticated and very comprehensive scale that combines the Scale for the Assessment 2 
of Negative Symptoms (SANS) (Andreasen, 1983a) and the Scale for the Assessment of Positive 3 
Symptoms (SAPS) (Andreasen, 1983b).  4 
Method 5 
Subjects  6 
 Detailed descriptions of the sample and primary results on short-term efficacy from this 7 
naturalistic randomized clinical trial, which compared effectiveness of treatments with 8 
risperidone, olanzapine and haloperidol, have been published elsewhere (Pelayo-Teran et al., 9 
2008). Briefly, the patients were recruited from an epidemiological catchment area in northern 10 
Spain, where the annual incidence of psychosis has been estimated to be 1.38/10,000 inhabitants. 11 
Inclusion criteria were: 1)  age between 15-60 years; 2) experiencing a first episode of psychosis; 12 
3) DSM-IV principal diagnosis of schizophrenia, schizophreniform disorder, schizoaffective 13 
disorder, brief psychotic disorder or psychosis not otherwise specified; 4) usually living in the 14 
catchment area; 5) no prior treatment with antipsychotic medication or, if previously treated, a 15 
total life time of adequate antipsychotic treatment of less than 6 weeks; and 6) having current 16 
psychotic symptoms of moderate or greater severity, as assessed by one of the five SAPS items. 17 
Patients meeting these criteria and their families provided written informed consent to be 18 
included in the study, which conformed to international standards for research ethics and was 19 
approved by the local institutional review board. 20 
The diagnoses were confirmed by an expert psychiatrist according to the DSM-IV 21 
criteria, using the Structured Clinical Interview for DSM-IV (SCID–I). The diagnosis variable 22 
was defined as 1 (schizophrenia) or 0 (other non-affective psychoses).  23 
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 1 
 Both SANS (Andreasen, 1983a) and SAPS (Andreasen, 1983b) were used to assess 2 
schizophrenia symptom severity. The negative, positive and disorganized dimensions were 3 
calculated from the symptom scores provided by these scales, following previous literature 4 
(Grube et al., 1998). The Positive dimension was calculated as the sum of the global scores of 5 
Delusions and Hallucinations from SAPS (maximum score: 10); the Disorganized dimension 6 
was calculated as the sum of the global scores of Formal Thought Disorder, Bizarre and 7 
Inappropriate Behaviours from SAPS (maximum score: 15); and the Negative dimension was 8 
calculated as the sum of the global scores of Anhedonia/Associability, Avolition/Apathy, 9 
Affective Blunting and Alogia in SANS (Maximum score: 20). Variables analyzed as potential 10 
predictive factors were gender, duration of untreated psychosis (DUP), presence or absence of 11 
cannabis use (a patient who consumed cannabis at least once per week during the year previous 12 
to psychosis onset was considered a cannabis consumer), antipsychotic type, smoking and 13 
diagnosis (schizophrenia versus other psychoses). The selection of these variables was based on 14 
previous analyses of short and medium term responses observed in this trial (Crespo-Facorro et 15 
al., 2007; Caseiro et al., 2012; Diaz et al., 2012).  The study included 174 patients. Out of these, 16 
a total of 161 provided SANS-SAPS scores at all investigated time points (baseline and at the 17 
ends of weeks 1, 2, 3, 4 and 6). Only these 161 patients were used to build a model of trajectories 18 
of antipsychotic response. 19 
Statistics 20 
 A censored normal model of response trajectories was developed by using the positive 21 
dimension of the SAPS-SANS scores (Jones et al., 2001). This model allowed identifying the 22 
various trajectories of this dimension during the 6-week period. Once these different trajectories 23 
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were identified, the model allowed estimating the effect of gender, DUP, cannabis use, 1 
antipsychotic type, smoking and diagnosis on the probabilities that a patient has the identified 2 
trajectories.    3 
 The optimal number of group trajectories was identified by using the Bayesian 4 
Information Criterion (Jones et al., 2001). Initially, cubic trajectories were used in all groups. 5 
Once the optimal number of groups was identified, nonsignificant polynomial orders were 6 
removed from the model. Then, the effects of gender, DUP, cannabis use, antipsychotic and 7 
diagnosis on the probabilities of belonging to the group trajectories were investigated. A full 8 
model was fitted by including all these variables in the model, and then those variables that did 9 
not have a significant effect on any of these probabilities were removed from the model. The 10 
final model included only those variables that had some significant effects. SAS PROC TRAJ 11 
was used for computations (Jones et al., 2001). The model uses a generalized logit function to 12 
represent the effects of the variables. Thus, the effect (regression coefficient) of a variable on the 13 
probability of belonging to a particular trajectory group can be interpreted analogously to the 14 
way an effect is interpreted in logistic regression, with the understanding that the particular 15 
group is compared with only the reference group. 16 
Analogous models were built for the disorganized and negative dimensions of SAPS-17 
SANS scores. Sixteen patients who had a disorganized dimension equal to 0 were excluded from 18 
the analysis of this dimension for 2 reasons: 1) the normal model is a continuous model that does 19 
not allow a mixture of discrete and continuous distributions, and 2) it makes no sense to 20 
investigate the evolution of symptoms when there are no initial symptoms. For similar reasons, 21 
43 subjects who had a negative dimension equal to 0 were excluded from the analysis of this 22 
dimension. The censored normal model was also used to identify trajectories of the Brief 23 
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Psychiatric Rating Scale (BPRS) total score. 1 
Results 2 
Analysis of trajectories of antipsychotic treatment response: positive dimension 3 
 According to the final model, the patients were classified into 5 types depending on their 4 
change in the positive dimension of SAPS-SANS scores over time after antipsychotic treatment 5 
(Table 1 and Panel A in Figure 1). Observe that there is a group of subjects who did not respond 6 
or responded very poorly to antipsychotic treatment, according to the positive SAPS-SANS 7 
scores (Group 5; Figure 1-A). 8 
 The first group included patients with a mean baseline positive SAPS-SANS  score of 9 
5.0, and responded to treatment well, with a mean score close to 0 at the end of the 6
th
 week of 10 
treatment (Group 1 in Figure 1-A). We call patients following this trajectory “Responders”. The 11 
second group of patients had a very high mean baseline score, 10.0, but their scores had been 12 
dramatically reduced to nearly 0 at the end of the 6
th
 week (Group 2); we named patients 13 
following this trajectory “Dramatic Responders”. The third group had an initial mean score of 14 
5.8, and a final score of 2.8 (Group 3); and we called these patients “Partial Responders”. The 15 
fourth group of patients had an initially high mean score, 9.7, but their mean score dropped 16 
substantially to 2.6 during the first 6 weeks of treatment (Group 4). Given that these patients 17 
exhibited a high degree of response but the severity of symptoms at the end of the 6
th
 week was 18 
similar to that of the Partial Responders they were called “Slow Partial Responders”. The fifth 19 
group had the highest positive SAPS-SANS scores and did not appear to respond substantially to 20 
antipsychotic treatment during the 6-week follow-up, exhibiting a baseline score of 9.9 and a 21 
final score of 7.9 (Group 5). Patients on this trajectory were called “Non-Responders” 22 
 Patients in groups with higher label numbers tended to be more difficult to treat or to 23 
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have a more severe illness than patients in groups with a lower label number. For instance, 1 
patients in the Non-Responders trajectory (Group 5) had a very high baseline positive SAPS-2 
SANS score and had a poorer response to antipsychotic treatment than patients in Group 3 3 
(Partial Responders).  4 
 Cannabis use and DUP had significant effects on the probabilities of having particular 5 
positive SAPS-SANS response trajectories (Table 2).  Antipsychotic type did not have 6 
significant effects on the probabilities of belonging to Groups 2 through 5 compared to Group 1 7 
(Table 2).  8 
Effect of cannabis use on positive dimension response trajectories 9 
 When comparing Non Responders versus Responders, cannabis users had significantly 10 
higher odds of being Non Responders than non-users (15.9 times higher, p=0.001; e
2.77 
=15.9). 11 
When comparing Slow Partial Responders with Responders, the odds that a cannabis user was a 12 
Slow Partial Responder was significantly higher than the odds for a non-user (7.3 times higher, 13 
p<0.001; e
1.99
=7.32). When comparing Partial Responders versus Responders, cannabis users 14 
had significantly higher odds of being Partial Responders than non-users (4.4 times higher, 15 
p=0.006; e
1.48 
=4.4, Table 2).  16 
Interestingly, Table 2 shows that there was a gradient in the effect of cannabis use on the 17 
severity of (and difficulty in treating) the illness. Parameter estimates show that the effect of 18 
cannabis use on the probability of belonging to a particular group increased with illness severity 19 
and difficulty in treating the patients in the group (1.01 for Group 2 versus Group 1; 1.48 for 20 
Group 3; 1.99 for Group 4; and 2.77 for Group 5).  21 
Effect of DUP on positive dimension response trajectories 22 
 When comparing Non-Responder patients versus Responders, higher DUPs were 23 
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significantly associated with higher odds of being a Non-Responder (p=0.006; Table 2).  When 1 
focusing on these two subpopulations of patients, each additional year of DUP increased 2 
significantly the odds of being a Non-Responder by 5.8% [(e
0.056
-1) × 100=5.8]. Analogous 3 
conclusions were obtained when comparing Slow Partial Responders with  Responders (p=0.02), 4 
and Partial Responders with Responders (p=0.01).  5 
 Gender, smoking and diagnosis did not significantly affect the type of response trajectory 6 
after controlling for antipsychotic treatment, cannabis use and duration of untreated psychosis, 7 
according to the positive dimension of the SAPS-SANS score. 8 
Analysis of trajectories of antipsychotic treatment response: disorganized dimension 9 
 Three types of trajectories were identified for the disorganized dimension of SAPS-SANS 10 
scores. Table 1 and Figure 1 (Panel B) show the trajectories and the proportions of patients 11 
exhibiting the trajectories.  Group 1 in Figure 1-B included patients with a mean baseline 12 
disorganized SAPS-SANS  score of 7.5, and responded to treatment well, with a mean score of 13 
0.6 at the end of the 6
th
 week of treatment; we call patients following this trajectory 14 
“Responders”. Group 2 had patients with a mean baseline score of 5.0, and their scores 15 
dramatically reduced to nearly 0 at the end of the 6
th
 week; these patients were named “Dramatic 16 
Responders”. Group 3 had a high initial mean score of 10.7, and a final score of 5.4 (“Partial 17 
Responders”). When comparing Dramatic Responders versus Responders, cannabis users had 18 
significantly lower odds of being Dramatic Responders than non-users [65.4% lower, p=0.03; 19 
(e
−1.06
 -1)×100=−65.4; Table 2]. Antipsychotic treatment, gender, DUP, smoking and diagnosis 20 
did not have significant effects on the probabilities of having a particular trajectory after 21 
adjusting for cannabis use. 22 
Analysis of trajectories of antipsychotic treatment response: negative dimension 23 
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 Five types of trajectories were identified for the negative dimension of SAPS-SANS 1 
score (Table 1 and Panel C in Figure 1). Observe that two trajectories were constant or nearly 2 
constant (corresponding to Groups 2 and 3). Patients in these two groups were non-reponders 3 
and could be differentiated regarding the severity of the symptoms exhibited. Group 2 included 4 
patients with a mean initial score of 4.7 and a final score of 4.3 in the negative SANS dimension; 5 
we called these patients “Mild Non-Responders”. Group 3 comprised patients with mean initial 6 
and final scores of 8.1, called “Moderate Non-Responders”. The other three groups showed some 7 
degree of response during the 6-week follow-up. Group 1 included patients with mild symptoms 8 
(initial mean score of 3.8) and a reduction to nearly 0 at the end of the follow-up (“Responders”). 9 
Group 4 included patients with initially high negative scores (mean, 13.9) and a progressive 10 
reduction to a mean score of 3.2 (“Partial Responders”). Finally, Group 5 included the patients 11 
with both the highest negative scores and weakest responses over the investigated period (“Poor 12 
Responders”).  Only diagnosis had significant effects on the probabilities of following particular 13 
trajectories of negative symptoms (Table 2). For instance, when comparing Poor Responders 14 
versus Responders, schizophrenia patients had significantly higher odds of being Poor 15 
Responders than patients without schizophrenia (4.6 times higher, e
1.53
 =4.6, p=0.04). Analogous 16 
results were obtained when comparing Partial Responders with Responders (p=0.03), and Mild 17 
Non-Responders with Responders (p=0.03). Interestingly, the probability of belonging to the 18 
peculiar group with a constant trajectory (Moderate Non-Responders) was not significantly 19 
affected by diagnosis when comparing this group with Responders.  20 
Trajectories of BPRS total scores 21 
Four trajectories for the BPRS total score were found, which were very similar to four of the five 22 
trajectories found for the SAPS-SANS positive dimension (Figure 2). That is, a group analogous 23 
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to that of the Slow Partial Responders of the SAPS-SANS positive dimension (Group 4 in Figure 1 
1A) was not observed in the BPRS total score.  2 
Discussion 3 
 Our results show a remarkable interindividual variation in the response to treatment in 4 
patients with a first episode of psychosis, which replicates and extends previous research. We 5 
found different numbers of trajectories across the three analyzed symptomatic dimensions:  5 6 
trajectories for the positive dimension, 3 for the disorganized dimension and 5 for the negative 7 
dimension. The dimensions changed differentially over time; their changes had associated 8 
predictor factors that are discussed below. 9 
Trajectories of SAPS-SANS positive dimension 10 
 Similarly to previous reports that focused on positive symptoms using other scales 11 
(Stauffer et al., 2011; Levine & Leucht, 2012; Levine et al., 2012), we identified 5 response 12 
trajectories. In our study, only 8.3% of the patients were included in a trajectory of Non-13 
Responders (patients with both a high level of initial psychotic symptoms and a poor level of 14 
improvement over the 6-week follow-up). Two groups with marked differences in initial severity 15 
(Responders and Dramatic Responders) included patients with a substantial response and the 16 
mildest final severity, accounting for 37.6% of the sample. Finally, two more groups (Slow 17 
Partial Responders with a high initial severity and Partial Responders with an intermediate initial 18 
severity) showed intermediate responses with mild to moderate severity of positive dimension 19 
scores at week 6.  20 
 Our results showing 5 different response trajectories are similar to previous reports 21 
describing this same number of trajectories (Stauffer et al., 2011; Levine & Leucht, 2012; Levine 22 
et al., 2012). However, the groups markedly differed in the implications of response course. 23 
14 
 
 
 
Previous studies typically found one group of “dramatic responders”, characterized by high 1 
(Marques et al., 2011) or medium (Case et al., 2011; Levine & Leucht, 2012; Levine et al., 2012) 2 
initial symptom severity and a rapid and more complete response over time, accounting for 2.4 – 3 
22% of the patients. Similarly to our results, the study by Marques et al., (2011) which used the 4 
BPRS positive subscale, found two groups of patients who had a rapid and very complete 5 
response, and accounted for 32.2% of the sample. Levine and Rabinowitz (2010) described a 6 
pattern of five trajectories for the PANSS positive subscale, with a group that had a rapid and 7 
considerable improvement (17.1% of the patients), and 4 groups differentiated by the severity of 8 
the scores along follow-up.  Another study that analyzed positive and negative subscales of 9 
PANSS  found only three different trajectories for the PANSS positive subscale and one of the 10 
trajectories was interpreted as a “rapid symptom improvement” (Case et al., 2011). However, 11 
this study used a different statistical methodology.   12 
 Differences in conclusions between this and previous studies may also be due to the fact 13 
that previous studies used total PANSS or BPRS scores as symptomatology ratings. BPRS and 14 
PANSS positive scales included items representing disorganized symptoms, making it difficult to 15 
translate results in terms of severity or thresholds and to make comparisons. According to our 16 
results, the trajectories of these two dimensions may be quite different and combining symptoms 17 
of disorganization with reality distortion may bias the results in trajectory analyses. In contrast 18 
with some previous studies, we were not able to find any trajectories that could be identified as 19 
“unsustained response” (Case et al., 2011; Stauffer et al., 2011) or “delayed response” (Stauffer 20 
et al., 2011). However, the short follow-up of our study may have not allowed identifying these 21 
types of trajectory. In this regard, trajectories such as those of Partial responders or Slow Partial 22 
Responders for positive symptoms could be identified as delayed-response or unsustained-23 
15 
 
 
 
response trajectories in a longer follow-up study.  The high response rates in our sample may be 1 
due to characteristics of the sample, as first-episode psychosis patients usually have better 2 
responses to antipsychotic treatment.  3 
 With regard to predictor factors, only longer DUPs and cannabis use were associated with 4 
trajectories of worse outcome and we did not find any influence of gender, diagnosis, smoking or 5 
antipsychotic class.  Our results are not strictly comparable to previous studies of symptom 6 
trajectories, as previous research has focused on aggregate data of symptoms instead of symptom 7 
dimensions and examined different predictors. However, not having a schizophrenia diagnosis 8 
(Levine & Rabinowitz, 2010), good premorbid and cognitive functioning (Levine & Rabinowitz, 9 
2010; Levine et al., 2010) and female gender have been associated with better response 10 
trajectories, whereas dropping out of the study has been associated with trajectories of worse 11 
response (Levine & Leucht, 2010; Levine et al., 2012). Factors such as age at psychosis onset 12 
and initial symptom severity have shown contradictory results in previous studies (Case et al., 13 
2011; Levine & Leucht, 2010; Levine & Rabinowitz, 2010; Levine et al., 2010; Stauffer et al., 14 
2011). Discrepancies in results may also be explained by the use of chronic samples by previous 15 
studies. With regard to DUP and cannabis use, only one previous study analyzed these factors, 16 
but it was unable to find significant associations between these factors and different response 17 
trajectories (Levine et al., 2010). Our observed association between longer DUPs and worse 18 
response trajectories is in agreement with previous research that showed a relationship between 19 
longer DUPs and poorer response of positive symptoms (Perkins et al., 2005) and other symptom 20 
and outcome dimensions.  Similarly, substance use disorders, particularly cannabis use, have 21 
been related to both a poor prognosis in schizophrenia (Kerfoot et al., 2011) and higher rates of 22 
psychotic symptoms such as hallucinations and thought disorders (Buhler et al., 2002).  23 
16 
 
 
 
 With regard to antipsychotic treatment we were not able to find any differences in the 1 
response trajectories of the investigated dimensions across the three investigated antipsychotics 2 
(haloperidol, risperidone and olanzapine), but we cannot rule out the possibility that including 3 
other antipsychotics may contribute to differences. However, the lack of a differential response is 4 
consistent with our previous analysis of effectiveness in our sample, which did not show any 5 
differences in the positive or negative symptoms across various antipsychotic treatments, 6 
(Crespo-Facorro et al., 2006) and with a previous meta-analysis that suggested that the efficacy 7 
of atypical antipsychotics is similar to that of haloperidol when controlling for dosage (Geddes et 8 
al., 2000). Similarly, no differences have been found between the response trajectories of 9 
risperidone and amisulpride (Levine & Leucht, 2010). However, previous studies found that 10 
“dramatic response” curves were associated with ziprasidone treatment when compared to 11 
quetiapine, risperidone, olanzapine and aripiprazole, whereas aripiprazole was associated with 12 
“delayed response curves” (Stauffer et al., 2011). Additionally, a post hoc study based on CATIE 13 
study phase 1 showed that patients treated with olanzapine were more likely to belong to the 14 
trajectory of responders when compared with patients treated with perphenazine, risperidone, 15 
quetiapine and ziprasidone (Levine et al., 2012). These results, however, may be mediated, at 16 
least in part, by the heterogeneity induced by patients’ chronicity, high drop-out rates and follow-17 
up length. 18 
It is remarkable that the results of this study concerning the SAPS-SANS positive 19 
dimension are very similar to results obtained by previous studies, despite the fact that a 20 
substantially different statistical modeling approach was used. The modeling approach used in 21 
our study essentially consists of two steps (Jones, 2001). In the first step, the probability 22 
distribution of the positive dimension score at the end of a particular week of treatment is 23 
17 
 
 
 
assumed to be a mixture of an unknown number of probability distributions. It is also assumed 1 
that this unknown number is the same across weeks, and that the means of these distributions are 2 
related with the number of weeks under treatment in a way described by a polynomial equation 3 
(Table 1). The main goal of the first step is to identify this unknown number which, in our 4 
context, is the number of “trajectories”. In the second step, the effect of predictor factors on the 5 
“risk” that a particular dimension score comes from a particular probability distribution is 6 
modeled in a way analogous to the way a risk is modeled in multinomial logistic regression, 7 
assuming that the effect of a particular predictor is the same across weeks. In fact, if only two 8 
probability distributions were identified in the first step, the second step essentially fitted the 9 
usual logistic regression model that epidemiologists are accustomed to use. A natural 10 
consequence of this approach is that odds ratios can be computed and interpreted in the same 11 
way as in logistic regression, as we did in the Results Section. The overall modeling approach, 12 
however, does not require that the “risk” of coming from a particular probability distribution (i.e. 13 
the risk that a subject follows a particular trajectory) be computed prior to estimating the effects 14 
of the predictors on this risk, because the mixture distribution used in the first step and the 15 
multinomial regression model of the second step are mathematically coupled during the 16 
estimation of predictor effects.  17 
On the other hand, previous studies have used latent growth curve modeling, which 18 
essentially uses covariance structure models that treat the parameters of the equations that 19 
describe the trajectories as random variables governed by continuous probability distributions. In 20 
contrast, the approach used in our study assumes that these parameters are fixed, non-random 21 
quantities and, as described above, assumes a substantially different mathematical structure for 22 
18 
 
 
 
the probability of following a particular trajectory and the way predictor variables are related 1 
with this probability.  2 
 3 
Trajectories of SAPS-SANS disorganized dimension  4 
 Three trajectories were identified in the response of disorganized dimension, which were 5 
almost parallel (Figure 2). Interestingly, the 66.7% of patients with a Dramatic Response (Group 6 
2) had a moderate initial severity of disorganized symptoms and on average responded rapidly 7 
and almost completely, suggesting a better response pattern in disorganized symptoms for these 8 
patients. Cannabis use was the only investigated factor that was significantly associated with 9 
higher severity and poorer response in disorganized symptoms, in accordance with previous 10 
research on substance abuse and schizophrenia (Buhler et al., 2002). To our knowledge this is the 11 
first randomized trial that investigated the trajectories of response of disorganized dimension 12 
symptoms in schizophrenia, despite the well-established existence of the dimension in 13 
schizophrenia along with the negative and positive dimensions (Arndt et al., 1995). In the studies 14 
of Marques et al. (2011), Case et al. (2011) and Levine and Rabinowitz, (2010),  in which 15 
positive and negative symptoms were analyzed independently, disorganized symptoms were 16 
combined with reality distortion  psychotic symptoms (delusions and hallucinations) by using the 17 
positive subscale of BPRS or the PANSS. The aggregation of symptoms that potentially may 18 
change differently over time makes it difficult to assess response heterogeneity and may partly 19 
explain differences across results from different studies and differences concerning the factors 20 
affecting these trajectories.  21 
Trajectories of SAPS-SANS negative dimension 22 
19 
 
 
 
 Our study identified five response trajectories for the negative dimension, which 1 
exhibited substantially different patterns if compared to the other two symptom dimensions. Mild 2 
Non-Responders and Moderate Non-Responders together accounted for 55.6% of the sample, 3 
including patients who exhibited  initial mild to medium severity scores but showed minimal 4 
variation during the six-week investigated period, suggesting a persistent severity. The other 5 
three groups showed some degree of response. In particular, patients in the Responders trajectory 6 
had the mildest initial severity and showed the most complete response. Patients in the Partial 7 
Responders trajectory started from a high level of severity, but exhibited a rapid and strong 8 
response; however, their response was incomplete at the end of follow-up. Finally, patients in the 9 
Poor Responders trajectory exhibited the highest severity, with a mild response both initially and 10 
during follow-up. A recent study (Levine & Leucht, 2012) found a predominance of early 11 
response during the first two weeks of treatment compared to the following four weeks; 12 
however, this study also found a delayed onset response from days 42 to 60, suggesting that a 13 
long-term evaluation of negative symptoms is required. This implies that patients of our study 14 
other than Responders or Partial Responders may have shown additional changes in their 15 
negative symptoms if the follow-up had been extended beyond week 6. 16 
 Interestingly, previous studies that tried to identify trajectories of response in negative 17 
symptoms were not able to find a model for negative symptoms, (Marques et al., 2011) or found 18 
similar trajectories to those of the total score response (Levine & Rabinowitz, 2010; Case et al., 19 
2011). This may be due to the fact that most of the samples were comprised of chronic patients, 20 
enrolled at different stages of antipsychotic response. Responses may be influenced by the 21 
previous use of antipsychotic medication, increasing the heterogeneity of clinical presentation 22 
and response course. Additionally, although the PANSS and BPRS negative subscales measure a 23 
20 
 
 
 
similar construct to the SANS negative dimension, their correlation is moderate which may also 1 
explain differences in results (Czobor et al., 1991; Rabany et al., 2011).   2 
 The only factor associated with some trajectories of negative dimension was diagnosis.  3 
Schizophrenia patients had in general higher severity rates and poorer responses in the negative 4 
dimension. This result is in agreement with the general notion that negative symptoms are 5 
intrinsic to the pathology of schizophrenia and contribute to poor outcome and functioning in 6 
schizophrenia. In this respect, previous studies usually reported a higher severity of negative 7 
symptoms in patients with schizophrenia compared to other psychoses (Pini et al., 2004; Cuesta 8 
& Peralta, 1995; Bobes et al., 2010). An unexpected negative result is that we did not find an 9 
association between DUP and trajectories of the negative dimension.  10 
Trajectories of BPRS total scores 11 
The four trajectories found for the BPRS total scores were very similar to the four trajectories 12 
reported by Marques et al (2010). Analogously to the results in Marques et al. (2010), our 13 
patients can be classified into 4 groups  depending on their change in BPRS total scores over 14 
time after antipsychotic treatment:  Responders (Group 1 in Figure 2), Dramatic Responders 15 
(Group 2), Partial Responders (Group 3), and Non-Responders  (Group 4). In contrast to the 16 
results in Marques et al. (2010), a higher percentage of our patients were classified as Non-17 
Responders and Partial-Responders, and these particular groups of patients exhibited less 18 
improvement through follow-up. However, our results may not be strictly comparable to those of 19 
Marques et al. (2010), since these authors used the BPRS positive subscale and their sample 20 
included chronic patients who may be less responsive to treatment compared to first episode 21 
patients. As previously discussed, differences in the number of trajectories and the degree of 22 
21 
 
 
 
response between our study and previous studies may be accounted at least in part by the 1 
inclusion of different symptomatic domains in symptom assessments.  2 
Limitations 3 
 The present study has several limitations that should be taken into consideration. First, 4 
comparability with previous studies is reduced by the fact that responses were evaluated in 5 
different symptom dimensions of the SANS-SAPS scales. Our approach may allow a better 6 
understanding of the heterogeneity of response and may represent a much improved approach 7 
compared to previous studies. Secondly, the follow-up only included short-term responses and 8 
response trajectories may be different in the long term. Thirdly, the sample size limits the 9 
number of classes identified. Finally, the number of factors analyzed was small and did not 10 
include some of the factors investigated in previous studies. The sample size, however, limits the 11 
number of variables that can be analyzed.   12 
Clinical Implications 13 
Our results suggest that different patients follow different patterns of response and that the 14 
different symptomatic dimensions obey different trajectories over time. In the case of positive 15 
symptoms, such as reality distortion, a substantial reduction of symptoms would be expected in a 16 
great majority of patients. Even a third of the patients may remit during a short trial of six week 17 
of treatment. However, given that patients start from very different baseline severity scores and 18 
the response change is quite heterogeneous among groups, response rates at the initial two weeks 19 
of treatment may not be good predictors of the response at later weeks; for instance, Responder 20 
patients (Group 1) could be considered subjects with a low rate of response at week 1 but 21 
remitters at week 6. These trajectories may be modulated at least in part by modifiable factors 22 
such as cannabis use and longer DUPs and, therefore, our results may have preventive and 23 
22 
 
 
 
therapeutic implications in clinical settings.  In the disorganized dimension, our results suggest 1 
that most patients would be responsive but those subjects with more severe symptoms have a 2 
lower probability of achieving a complete response; and this severity may also be related to the 3 
use of cannabis. With regard to negative symptoms, the heterogeneity of responses seems to be 4 
considerably higher and the rate of response appears to be lower in the short-term, however a 5 
number of patients still appears to be responsive. Only factors related to the illness seem to be 6 
related to the response to antipsychotic treatment when negative symptoms are considered. 7 
Given the nature of these symptoms and the mechanisms involved in their modification, a short – 8 
term pharmacological treatment may not be sufficient to observe a complete effect on negative 9 
symptoms. 10 
Conclusions 11 
 The current naturalistic clinical trial investigated a representative sample of patients with 12 
a first episode of psychosis, and focused on the analysis of the changes of 3 symptom dimensions 13 
in response to antipsychotic treatment over the course of 6 weeks. Our results illustrate different 14 
patterns of short-term changes and trajectories in the psychotic reality distortion, disorganization 15 
and negative dimensions. Whereas our results on the trajectories of the positive dimension are 16 
comparable with results from previous studies that found a five-trajectory model, the 17 
disorganized and particularly the negative dimensions showed marked differences with previous 18 
reports, probably caused by differences in study designs and investigated populations. A number 19 
of predictor factors affected response heterogeneity: longer DUPs were associated with poorer-20 
outcome trajectories in the positive dimension, cannabis use was related to trajectories of worse 21 
outcome in the positive and disorganized dimensions, and negative-dimension trajectories with 22 
high overall symptom severity were associated with a diagnosis of schizophrenia.   23 
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Table 1. Identified groups of patients with different 6-week trajectories of response to 
antipsychotics, according to the positive, disorganized and negative dimension of SAPS-SANS. 
                                              Positive Dimension (N=161)      
Group (%, n)
a
  Trend  Estimate
b
 S.E.  p-Value Name    
1 (22.4%, 36)  Intercept 5.00  0.20 <0.001  Responders 
   Linear 
 
−1.01  0.08 <0.001      
2 (15.2%, 25)  Intercept 10.04  0.32 <0.001  Dramatic Responders 
   Linear 
 
−3.68  0.28 <0.001 
   Quadratic 0.33  0.04 <0.001      
3 (36.2%, 58)  Intercept 5.76  0.19 <0.001  Partial Responders 
   Linear 
 
−0.49  0.05 <0.001      
4 (17.9%, 29)  Intercept 9.73  0.27 <0.001        Slow Partial Responders 
   Linear 
 
1.06  0.48 0.03 
   Quadratic −1.01  0.21 <0.001 
   Cubic  0.11  0.02 <0.001      
5 (8.3%, 13)  Intercept 9.94  0.29 <0.001  Non-Responders 
   Linear 
 
−0.34  0.09 <0.001      
                                               Disorganized Dimension (N=145)      
Group   Trend  Estimate
a
 S.E. p-Value     
1 (23.3%, 34)  Intercept 7.47  0.50 <0.001  Responders 
   Linear 
 
−1.14  0.12 <0.001      
2 (66.7%, 96)  Intercept 4.95  0.25 <0.001  Dramatic Responders 
   Linear 
 
−2.83  0.23 <0.001 
   Quadratic 0.27  0.038 <0.001      
3 (10%, 15)  Intercept 10.72  0.54 <0.001  Partial Responders 
   Linear 
 
−0.89  0.16 <0.001      
                                               Negative Dimension (N=118)      
Group   Trend  Estimate
a
 S.E. P-Value     
1 (18.8%, 22)  Intercept 3.84  0.66 <0.001  Responders 
   Linear 
 
−3.31  0.70 <0.001 
   Quadratic 0.41  0.11 <0.001      
2 (37.3%, 44)  Intercept 4.67  0.47 <0.001            Mild Non-Responders 
   Linear 
 
−0.85  0.35   0.02     
   Quadratic 0.13  0.05   0.02      
3 (18.3%, 22)  Intercept 8.09  0.37 <0.001     Moderate Non-Responders 
4 (11%, 13)  Intercept 13.9  0.88 <0.001  Partial Responders 
   Linear 
 
−3.70  0.63 <0.001 
   Quadratic 0.32  0.10 0.001      
5 (14.5%, 17)  Intercept 16.05  0.50 <0.001  Poor Responders 
   Linear 
 
−0.87  0.15 <0.001      
S.E.: Standard error. 
a
This column reports the estimated percentage (%) and estimated number (n) of subjects that 
belong to the group. The number n was inferred from the estimated percentage and N 
(estimated percentage times N/100).  
b
For each group of patients, these column shows the coefficients of the polynomial function 
that describes each dimension of SAPS-SANS scores as a function of time.  These functions are 
plotted in Figure 1 (A, B and C) as dashed lines. 
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Table 2. Variables significantly affecting the probabilities that a patient has particular types of 
response to antipsychotics when the response is measured with SAPS-SANS dimension scores. 
                                                         Positive Dimension       
Group Variable  Estimate S.E.  p-Value Name    
1
a
 ---   ---  ---  ---  Responders   
2 Olanzapine
 b,c
  −0.15  0.67  0.8  Dramatic Responders 
 Risperidone
 c,d  
−0.85  0.63  0.2 
 Cannabis
e  
1.01  0.56  0.07 
 DUP   −0.02  0.03  0.6      
3 Olanzapine
 b,c
  0.96  0.66  0.1  Partial Responders 
 Risperidone
 c,d  
−0.16  0.62  0.8 
 Cannabis
e  
1.48  0.54  0.006 
 DUP   0.05  0.02  0.01      
4 Olanzapine
 b,c
  0.57  0.70  0.4      Slow Partial Responders 
 Risperidone
 c,d  
−0.29  0.65  0.7 
 Cannabis
e  
1.99  0.58  <0.001 
 DUP   0.05  0.02  0.02      
5 Olanzapine
 b,c
  −0.26  1.03  0.8  Non-Responders 
 Risperidone
 c,d  
−0.02  0.78  0.98 
 Cannabis
e  
2.77  0.84  0.001 
 DUP   0.056  0.021  0.006      
                                                      Disorganized Dimension       
Group Variable  Estimate S.E.  p-Value     
1
a
 ---    ---   ---  ---  Responders   
2 Olanzapine
 b,c
  −0.22  0.61  0.7  Dramatic Responders 
 Risperidone
 c,d  
−0.30  0.57  0.6 
 Cannabis
e  
−1.06  0.48  0.03      
3 Olanzapine
 b,c
    0.20  0.93  0.8  Partial Responders 
 Risperidone
 c,d    
0.23  0.83  0.8 
 Cannabis
e  
−0.15  0.71  0.8      
                                                          Negative Dimension       
Group Variable  Estimate S.E.  p-Value     
1
a
 ---    ---   ---  ---  Responders   
2 Olanzapine
 b,c
  0.26  0.86  0.8  Mild Non-Responders 
 Risperidone
 c,d  
0.17  0.77  0.8 
 Schizophrenia
f 
1.40  0.66  0.03      
3 Olanzapine
 b,c
  −1.27  0.98  0.2     Moderate Non-Responders 
 Risperidone
 c,d  
−0.77  0.80  0.3 
 Schizophrenia
f  
0.60  0.73  0.4      
4 Olanzapine
 b,c
   0.95  1.02  0.4  Partial Responders 
 Risperidone
 c,d  
−0.26  1.07  0.8 
 Schizophrenia
f  
2.10  0.98  0.03      
5 Olanzapine
 b,c
   0.76  1.01  0.5  Poor Responders 
 Risperidone
 c,d 
  0.99  0.93  0.3  
 Schizophrenia
f  
1.53  0.75  0.04      
S.E.: Standard error. 
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a
Group 1 was the reference group. 
b
The olanzapine variable was defined as 1 if the patient was on olanzapine, 0 otherwise. 
c
The reference treatment was haloperidol 
d
The risperidone variable was defined as 1 if the patient was on risperidone, 0 otherwise. 
e
The cannabis use variable was defined as 1 if the patient had smoked cannabis at least once per 
week during the year previous to psychosis onset, 0 otherwise 
f
The schizophrenia variable was defined as 1 if the patient had a diagnosis of schizophrenia,  0 
otherwise. 
 
